Clinical Trial Update: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of binimetinib, encorafenib, and pembrolizumab, with or without stereotactic radiosurgery, for BRAFV600-mutant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• KEYTRUDA (PEMBROLIZUMAB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: UNICANCER | Conditions: Malignant Melanoma, BRAF V600 Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING